Welcome to our dedicated page for Connect Biopharma Holdings SEC filings (Ticker: CNTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Connect Biopharma Holdings Limited (CNTB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents filed with the Securities and Exchange Commission. These filings give investors structured insight into the clinical, financial, and corporate events that shape this clinical-stage biopharmaceutical company focused on asthma, COPD, and related inflammatory diseases.
Connect Biopharma’s recent Forms 8-K have covered topics such as quarterly financial results, business updates, and material corporate actions. Examples include announcements of second and third quarter financial results, the initiation and progress of Phase 2 Seabreeze STAT asthma and COPD studies for rademikibart, and the company’s decision to terminate its American Depositary Receipt program and directly list its ordinary shares on the Nasdaq Global Market. Other 8-K filings describe board changes, including the appointment of an additional director, and regulatory milestones such as the submission of a New Drug Application for rademikibart in atopic dermatitis by the company’s exclusive licensee in China.
Filings also document insider-related information and regulatory disclosures under Regulation FD, such as updates on share purchases by senior executives and communications about collaboration activities with Simcere Pharmaceutical Co., Ltd. in Greater China. These documents complement Connect Biopharma’s press releases by providing formal, SEC-compliant descriptions of material events.
On Stock Titan, CNTB filings are updated as new documents are posted to the SEC’s EDGAR system. Users can review individual filings to understand how Connect Biopharma reports its clinical progress with rademikibart, capital markets decisions, governance changes, and other significant developments that may be relevant to an assessment of CNTB stock.
Xanthopoulos Kleanthis Gabriel reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos received a grant of 2,816 ordinary shares on March 31, 2026. These fully vested shares were taken in lieu of a portion of cash compensation for his 2026 annual board retainers for service in the first quarter of 2026. After this award, he directly holds 82,816 ordinary shares of the company.
LIU JEAN I reported acquisition or exercise transactions in this Form 4 filing.
Connect Biopharma Holdings Ltd director Jean I. Liu received a stock grant of 5,061 ordinary shares as board compensation. The shares are fully vested and were taken in lieu of cash for her 2026 annual board retainers, covering service during the first quarter of 2026.
The number of shares was calculated by dividing the applicable equity value by the average closing price of the company’s ordinary shares over the 30 consecutive trading days immediately before March 31, 2026, then rounded down to the nearest whole share. This is a routine, compensation-related equity award rather than an open‑market purchase or sale.
Connect Biopharma Holdings Ltd director-linked entity reports major share purchase. An entity associated with James Huang completed an open-market purchase of 1,160,000 Ordinary Shares at $3.45 per share. After this transaction, the filing shows 13,160,000 Ordinary Shares held indirectly. The shares are recorded under Panacea Venture Healthcare Fund II, L.P., and Huang may be deemed to share beneficial ownership but expressly disclaims such beneficial ownership.
Panacea Venture Healthcare Fund II, L.P. and affiliated entities filed an amended beneficial ownership report on Connect Biopharma Holdings, showing 13,160,000 Ordinary Shares, or 21.2% of the class, with shared voting and dispositive power.
On March 31, 2026, Panacea purchased 1,160,000 Ordinary Shares at $3.45 per share in a 6,130,000-share offering. The Issuer agreed to file a resale registration statement within 45 days of closing, and James Huang entered a 45-day lock-up restricting sales of his Ordinary Shares.
Connect Biopharma Holdings Limited provides an annual overview of its business as a clinical-stage company focused on asthma and COPD. The lead asset, rademikibart, is a next-generation antibody targeting IL‑4Rα, being developed first for acute exacerbations of asthma and COPD and then for chronic use.
Two Phase 2 trials (Seabreeze STAT ASTHMA and Seabreeze STAT COPD) are testing rademikibart plus standard of care versus placebo in patients with Type 2 inflammation, with treatment failure over 28 days as the primary endpoint. A Phase 1 IV study in stable asthma and COPD showed rapid FEV1 improvements within 15 minutes after a single 300 mg IV push, sustained to Day 29, and the drug was generally well tolerated.
The company highlights strong prior Phase 2b asthma and atopic dermatitis data, plus a Greater China license with Simcere, from which it has received $21 million upfront and $6.5 million in milestones and cost reimbursements, with up to about $110 million in potential additional milestones and tiered royalties. Key risks include heavy reliance on rademikibart, substantial future financing needs, intense biologics competition, and extensive U.S. and PRC regulatory, data security and geopolitical uncertainties.
Connect Biopharma reported 2025 full-year results showing it remains a clinical-stage company investing heavily in rademikibart. License and collaboration revenue was $64,000 for 2025, down from $26.0 million in 2024, reflecting the absence of prior-year upfront and milestone payments. Research and development expense rose to $37.8 million and general and administrative expense to $20.3 million, driving a wider net loss of $55.5 million, or $1.00 per share, compared with $15.6 million, or $0.28 per share, in 2024. Cash, cash equivalents and short-term investments were $44.3 million as of December 31, 2025. The company entered a $20.2 million private placement of 6,130,000 ordinary shares at $3.25 per share, which, together with existing cash, is expected to fund operations into the second half of 2027. Clinically, Connect reported positive Phase 1 IV rademikibart data in asthma and COPD with rapid FEV1 improvements of about 200–400 mL maintained through Day 29, alongside strong Phase 3 atopic dermatitis results from partner Simcere and ongoing Phase 2 Seabreeze STAT studies with topline data expected mid‑2026.
Connect Biopharma Holdings Limited entered a securities purchase agreement for a private placement of 6,130,000 ordinary shares at $3.25 per share, raising approximately $20.2 million in gross proceeds. The company plans to use the funds for clinical R&D, other development programs, working capital and general corporate purposes, and now expects its cash resources to fund operations into the second half of 2027.
The 8-K also highlights positive topline Phase 1 data for intravenous rademikibart in asthma and COPD, where a single 300 mg 2-minute IV push produced rapid and clinically meaningful FEV1 improvements of about 200–400 mL maintained through Day 29 with a favorable safety profile. In addition, partner Simcere reported Phase 3, 52-week results in atopic dermatitis, with high proportions of patients achieving deep skin clearance endpoints and safety comparable to placebo, supporting rademikibart’s potential as a best-in-class IL‑4Rα antibody.
Connect Biopharma Holdings Ltd director James Huang filed an initial Form 3 showing indirect exposure to the company’s Ordinary Shares. The filing reports that Panacea Venture Healthcare Fund II, L.P. is the record holder of 12,000,000 Ordinary Shares, with Huang linked through a chain of ownership interests in related entities. The footnote explains that Huang may be deemed to share beneficial ownership of these shares but expressly disclaims such beneficial ownership, indicating the position is held at the fund level rather than as a direct personal holding.
Connect Biopharma Holdings Ltd president David Leslie Szekeres filed an initial Form 3 reporting his equity holdings in the company. He directly holds 215,739 ordinary shares and several employee stock option grants over ordinary shares with exercise prices of $1.77, $0.97, and $2.69, expiring between 2034 and 2035. The footnotes explain that these options vest over four years, with portions vesting on the first anniversary of grant and the remainder vesting monthly thereafter, contingent on his continued service.
Connect Biopharma Holdings Ltd Chief Executive Officer Barry D. Quart filed an initial ownership report showing a mix of stock options and ordinary shares. He holds employee stock options over 2,658,734, 432,392, and 700,000 ordinary shares with exercise prices of $1.77, $0.97, and $2.69, expiring between 2034 and 2035. The options vest over four years, with portions vesting on the first anniversary of grant and the balance vesting monthly thereafter, subject to continuous service. Quart also reports direct ownership of 95,147 ordinary shares and indirect ownership of 128,887 ordinary shares through a joint account with his spouse.